Tirzepatide: the dual GIP and GLP-1 receptor agonist

The chemistry behind the once-weekly half-life

A bare 39-amino-acid peptide injected into the body would be cleared in hours. Modern long-acting peptide design solves this with a lipid modification that hijacks the abundance of serum albumin, the most plentiful protein in plasma. The fatty acid sticks to albumin reversibly, which dramatically slows the rate at which the molecule is cleared by the kidneys.

For tirzepatide, the modification is a C20 fatty diacid (a 20-carbon dicarboxylic acid chain) attached to the side chain of lysine 20 through a linker built from a gamma-glutamic-acid residue plus two units of AEEA (8-amino-3,6-dioxaoctanoic acid). The same chemistry concept appears across the family of long-acting peptides: semaglutide uses a C18 diacid with a similar linker arrangement, and retatrutide uses its own variation. The choice of chain length, linker length, and attachment residue is the technical lever that determines exactly how long the molecule sits in circulation.

For the bench scientist, the practical implication is that tirzepatide reconstitutes cleanly into a clear colourless solution and behaves as a long-half-life lipopeptide in any research model that involves serum albumin. The molecule is not unusually fragile but it does have specific handling preferences (cold chain, amber glass, no shaking) that the lipid modification reinforces, since shear and foaming can affect the lipid micellisation behaviour of the reconstituted solution.

The SURPASS and SURMOUNT trial data

The phase 3 programme was, in scale and pace, one of the more ambitious published peptide development programmes of the last decade. Two parallel series:

SURPASS (type 2 diabetes)

Five trials in adults with type 2 diabetes, against placebo, semaglutide, insulin glargine, and insulin degludec. The pivotal head-to-head was SURPASS-2 (Frias et al., NEJM 2021, PMID 34170647) which compared tirzepatide 5, 10 and 15 mg weekly against semaglutide 1 mg weekly. Tirzepatide produced larger reductions in HbA1c and in body weight at every dose level.

SURMOUNT-1 (obesity, no diabetes)

72-week trial in adults with obesity but without type 2 diabetes, published as Jastreboff et al. NEJM 2022, PMID 35658024. The headline numbers are the ones that propagated through the entire metabolic-research conversation:

SURMOUNT-2 (in adults with type 2 diabetes plus obesity) reported a mean reduction of 14.7 percent at the 15 mg dose. SURMOUNT-3 (after intensive lifestyle intervention) and SURMOUNT-4 (continued treatment vs withdrawal) round out the obesity programme.

The licensing followed quickly. The FDA authorised Eli Lilly’s branded product, Mounjaro, for type 2 diabetes in May 2022. Zepbound, the same molecule under a different brand for chronic weight management, followed in November 2023. The MHRA authorised Mounjaro for type 2 diabetes in the UK and the product is now NHS-funded for patients meeting the relevant clinical criteria.

What to look for on the Certificate of Analysis

If you’ve read our walk-through of how to read a Janoshik HPLC report, the standard structure applies. For tirzepatide specifically, three things matter:

1. A single tall peak on the reversed-phase HPLC chromatogram

You want one dominant peak at the tirzepatide retention time, a flat baseline elsewhere, and 99%+ purity in the analytical summary. The tirzepatide market is the most actively counterfeited peptide segment globally right now, so the chromatogram trace itself matters more than the headline number. A report that quotes 99% purity but never shows you the trace is giving you a number you cannot verify.

2. Mass-spectrometry confirmation of the 4813.53 g/mol mass

Tirzepatide is large enough that on electrospray mass spectra you see multiply-charged species rather than a single intact molecular ion. The typical positive-ion charge states are [M+3H]3+ at m/z 1605.5, [M+4H]4+ at m/z 1204.4, [M+5H]5+ at m/z 963.7, and [M+6H]6+ at m/z 803.3. A real spectrum from Janoshik or any competent peptide-analysis lab will show a characteristic ladder of these charge states with the masses cross-summable back to 4813.53 g/mol average.

3. The Janoshik verification key resolves on their portal

Every Janoshik certificate carries a short alphanumeric verification key. That key, plus the task ID printed on the certificate, can be cross-referenced on the issuing lab’s public records. A real tirzepatide batch will resolve. A fabricated COA will not. Do this check yourself; do not take “verified” as a self-assertion from the supplier.

Storage and handling at your bench

• Refrigerate at 2–8 °C in the original sealed amber-glass vial. Tirzepatide is stable for 24 months or more in the lyophilised state when kept dry, sealed, and protected from light.
• Reconstitute with bacteriostatic water by adding the water slowly down the inside wall of the vial and gently swirling (not shaking, never vortexing) until the cake fully dissolves. The resulting solution should be clear and colourless. Cloudiness suggests undissolved peptide or contamination.
• Reconstituted shelf life is shorter than the lyophilised form. The published preclinical analytical literature commonly references stability over a window of four to six weeks under refrigeration; consult the specific assay or research method you are running for the exact figure for your context.
• Avoid freeze-thaw cycles on the reconstituted solution. The lipid modification makes tirzepatide micelle-prone and repeated freeze-thaw is the single most common cause of a previously good vial dropping in measurable activity.
• Ship and store in amber glass. Tirzepatide is less photolabile than copper-coordinated peptides like GHK-Cu, but cold-chain amber-glass shipping is the right default for any modern lipopeptide.

Common red flags when sourcing tirzepatide